NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis

Jacqueline G. O'Leary, K. Rajender Reddy, Guadalupe Garcia-Tsao, Scott W. Biggins, Florence Wong, Michael B. Fallon, Ram M. Subramanian, Patrick S. Kamath, Paul Thuluvath, Hugo E. Vargas, Benedict Maliakkal, Puneeta Tandon, Jennifer Lai, Leroy R. Thacker, Jasmohan S. Bajaj

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The North American Consortium for the Study of End-Stage Liver Disease's definition of acute-on-chronic liver failure (NACSELD-ACLF) as two or more extrahepatic organ failures has been proposed as a simple bedside tool to assess the risk of mortality in hospitalized patients with cirrhosis. We validated the NACSELD-ACLF's ability to predict 30-day survival (defined as in-hospital death or hospice discharge) in a separate multicenter prospectively enrolled cohort of both infected and uninfected hospitalized patients with cirrhosis. We used the NACSELD database of 14 tertiary care hepatology centers that prospectively enrolled nonelective hospitalized patients with cirrhosis (n = 2,675). The cohort was randomly split 60%/40% into training (n = 1,605) and testing (n = 1,070) groups. Organ failures assessed were (1) shock, (2) hepatic encephalopathy (grade III/IV), (3) renal (need for dialysis), and (4) respiratory (mechanical ventilation). Patients were most commonly Caucasian (79%) men (62%) with a mean age of 57 years and a diagnosis of alcohol-induced cirrhosis (45%), and 1,079 patients had an infection during hospitalization. The mean Model for End-Stage Liver Disease score was 19, and the median Child score was 10. No demographic differences were present between the two split groups. Multivariable modeling revealed that the NACSELD-ACLF score, as determined by number of organ failures, was the strongest predictor of decreased survival after controlling for admission age, white blood cell count, serum albumin, Model for End-Stage Liver Disease score, and presence of infection. The c-statistics were 0.8073 for the training set and 0.8532 for the validation set. Conclusion: Although infection status remains an important predictor of death, NACSELD-ACLF was independently validated in a separate large multinational prospective cohort as a simple, reliable bedside tool to predict 30-day survival in both infected and uninfected patients hospitalized with a diagnosis of cirrhosis. (Hepatology 2018;67:2367-2374).

Original languageEnglish (US)
Pages (from-to)2367-2374
Number of pages8
JournalHepatology
Volume67
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Fibrosis
End Stage Liver Disease
Survival
Gastroenterology
Infection
Hospices
Hepatic Encephalopathy
Leukocyte Count
Artificial Respiration
Tertiary Care Centers
Serum Albumin
Renal Dialysis
Acute-On-Chronic Liver Failure
Shock
Hospitalization
Alcohols
Demography
Databases
Mortality

ASJC Scopus subject areas

  • Hepatology

Cite this

O'Leary, J. G., Reddy, K. R., Garcia-Tsao, G., Biggins, S. W., Wong, F., Fallon, M. B., ... Bajaj, J. S. (2018). NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology, 67(6), 2367-2374. https://doi.org/10.1002/hep.29773

NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. / O'Leary, Jacqueline G.; Reddy, K. Rajender; Garcia-Tsao, Guadalupe; Biggins, Scott W.; Wong, Florence; Fallon, Michael B.; Subramanian, Ram M.; Kamath, Patrick S.; Thuluvath, Paul; Vargas, Hugo E.; Maliakkal, Benedict; Tandon, Puneeta; Lai, Jennifer; Thacker, Leroy R.; Bajaj, Jasmohan S.

In: Hepatology, Vol. 67, No. 6, 01.06.2018, p. 2367-2374.

Research output: Contribution to journalArticle

O'Leary, JG, Reddy, KR, Garcia-Tsao, G, Biggins, SW, Wong, F, Fallon, MB, Subramanian, RM, Kamath, PS, Thuluvath, P, Vargas, HE, Maliakkal, B, Tandon, P, Lai, J, Thacker, LR & Bajaj, JS 2018, 'NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis', Hepatology, vol. 67, no. 6, pp. 2367-2374. https://doi.org/10.1002/hep.29773
O'Leary, Jacqueline G. ; Reddy, K. Rajender ; Garcia-Tsao, Guadalupe ; Biggins, Scott W. ; Wong, Florence ; Fallon, Michael B. ; Subramanian, Ram M. ; Kamath, Patrick S. ; Thuluvath, Paul ; Vargas, Hugo E. ; Maliakkal, Benedict ; Tandon, Puneeta ; Lai, Jennifer ; Thacker, Leroy R. ; Bajaj, Jasmohan S. / NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. In: Hepatology. 2018 ; Vol. 67, No. 6. pp. 2367-2374.
@article{248cd27ec40e449f8c43b2700e30b1df,
title = "NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis",
abstract = "The North American Consortium for the Study of End-Stage Liver Disease's definition of acute-on-chronic liver failure (NACSELD-ACLF) as two or more extrahepatic organ failures has been proposed as a simple bedside tool to assess the risk of mortality in hospitalized patients with cirrhosis. We validated the NACSELD-ACLF's ability to predict 30-day survival (defined as in-hospital death or hospice discharge) in a separate multicenter prospectively enrolled cohort of both infected and uninfected hospitalized patients with cirrhosis. We used the NACSELD database of 14 tertiary care hepatology centers that prospectively enrolled nonelective hospitalized patients with cirrhosis (n = 2,675). The cohort was randomly split 60{\%}/40{\%} into training (n = 1,605) and testing (n = 1,070) groups. Organ failures assessed were (1) shock, (2) hepatic encephalopathy (grade III/IV), (3) renal (need for dialysis), and (4) respiratory (mechanical ventilation). Patients were most commonly Caucasian (79{\%}) men (62{\%}) with a mean age of 57 years and a diagnosis of alcohol-induced cirrhosis (45{\%}), and 1,079 patients had an infection during hospitalization. The mean Model for End-Stage Liver Disease score was 19, and the median Child score was 10. No demographic differences were present between the two split groups. Multivariable modeling revealed that the NACSELD-ACLF score, as determined by number of organ failures, was the strongest predictor of decreased survival after controlling for admission age, white blood cell count, serum albumin, Model for End-Stage Liver Disease score, and presence of infection. The c-statistics were 0.8073 for the training set and 0.8532 for the validation set. Conclusion: Although infection status remains an important predictor of death, NACSELD-ACLF was independently validated in a separate large multinational prospective cohort as a simple, reliable bedside tool to predict 30-day survival in both infected and uninfected patients hospitalized with a diagnosis of cirrhosis. (Hepatology 2018;67:2367-2374).",
author = "O'Leary, {Jacqueline G.} and Reddy, {K. Rajender} and Guadalupe Garcia-Tsao and Biggins, {Scott W.} and Florence Wong and Fallon, {Michael B.} and Subramanian, {Ram M.} and Kamath, {Patrick S.} and Paul Thuluvath and Vargas, {Hugo E.} and Benedict Maliakkal and Puneeta Tandon and Jennifer Lai and Thacker, {Leroy R.} and Bajaj, {Jasmohan S.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1002/hep.29773",
language = "English (US)",
volume = "67",
pages = "2367--2374",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis

AU - O'Leary, Jacqueline G.

AU - Reddy, K. Rajender

AU - Garcia-Tsao, Guadalupe

AU - Biggins, Scott W.

AU - Wong, Florence

AU - Fallon, Michael B.

AU - Subramanian, Ram M.

AU - Kamath, Patrick S.

AU - Thuluvath, Paul

AU - Vargas, Hugo E.

AU - Maliakkal, Benedict

AU - Tandon, Puneeta

AU - Lai, Jennifer

AU - Thacker, Leroy R.

AU - Bajaj, Jasmohan S.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The North American Consortium for the Study of End-Stage Liver Disease's definition of acute-on-chronic liver failure (NACSELD-ACLF) as two or more extrahepatic organ failures has been proposed as a simple bedside tool to assess the risk of mortality in hospitalized patients with cirrhosis. We validated the NACSELD-ACLF's ability to predict 30-day survival (defined as in-hospital death or hospice discharge) in a separate multicenter prospectively enrolled cohort of both infected and uninfected hospitalized patients with cirrhosis. We used the NACSELD database of 14 tertiary care hepatology centers that prospectively enrolled nonelective hospitalized patients with cirrhosis (n = 2,675). The cohort was randomly split 60%/40% into training (n = 1,605) and testing (n = 1,070) groups. Organ failures assessed were (1) shock, (2) hepatic encephalopathy (grade III/IV), (3) renal (need for dialysis), and (4) respiratory (mechanical ventilation). Patients were most commonly Caucasian (79%) men (62%) with a mean age of 57 years and a diagnosis of alcohol-induced cirrhosis (45%), and 1,079 patients had an infection during hospitalization. The mean Model for End-Stage Liver Disease score was 19, and the median Child score was 10. No demographic differences were present between the two split groups. Multivariable modeling revealed that the NACSELD-ACLF score, as determined by number of organ failures, was the strongest predictor of decreased survival after controlling for admission age, white blood cell count, serum albumin, Model for End-Stage Liver Disease score, and presence of infection. The c-statistics were 0.8073 for the training set and 0.8532 for the validation set. Conclusion: Although infection status remains an important predictor of death, NACSELD-ACLF was independently validated in a separate large multinational prospective cohort as a simple, reliable bedside tool to predict 30-day survival in both infected and uninfected patients hospitalized with a diagnosis of cirrhosis. (Hepatology 2018;67:2367-2374).

AB - The North American Consortium for the Study of End-Stage Liver Disease's definition of acute-on-chronic liver failure (NACSELD-ACLF) as two or more extrahepatic organ failures has been proposed as a simple bedside tool to assess the risk of mortality in hospitalized patients with cirrhosis. We validated the NACSELD-ACLF's ability to predict 30-day survival (defined as in-hospital death or hospice discharge) in a separate multicenter prospectively enrolled cohort of both infected and uninfected hospitalized patients with cirrhosis. We used the NACSELD database of 14 tertiary care hepatology centers that prospectively enrolled nonelective hospitalized patients with cirrhosis (n = 2,675). The cohort was randomly split 60%/40% into training (n = 1,605) and testing (n = 1,070) groups. Organ failures assessed were (1) shock, (2) hepatic encephalopathy (grade III/IV), (3) renal (need for dialysis), and (4) respiratory (mechanical ventilation). Patients were most commonly Caucasian (79%) men (62%) with a mean age of 57 years and a diagnosis of alcohol-induced cirrhosis (45%), and 1,079 patients had an infection during hospitalization. The mean Model for End-Stage Liver Disease score was 19, and the median Child score was 10. No demographic differences were present between the two split groups. Multivariable modeling revealed that the NACSELD-ACLF score, as determined by number of organ failures, was the strongest predictor of decreased survival after controlling for admission age, white blood cell count, serum albumin, Model for End-Stage Liver Disease score, and presence of infection. The c-statistics were 0.8073 for the training set and 0.8532 for the validation set. Conclusion: Although infection status remains an important predictor of death, NACSELD-ACLF was independently validated in a separate large multinational prospective cohort as a simple, reliable bedside tool to predict 30-day survival in both infected and uninfected patients hospitalized with a diagnosis of cirrhosis. (Hepatology 2018;67:2367-2374).

UR - http://www.scopus.com/inward/record.url?scp=85047864825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047864825&partnerID=8YFLogxK

U2 - 10.1002/hep.29773

DO - 10.1002/hep.29773

M3 - Article

C2 - 29315693

AN - SCOPUS:85047864825

VL - 67

SP - 2367

EP - 2374

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -